NCT04695925View on ClinicalTrials.gov

Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

November 1, 2025

Study Completion Date

December 30, 2027

Conditions
Non-small Cell CarcinomaEGFR Gene Mutation
Interventions
DRUG

Osimertinib

Osimertinib, 80mg, QD, p.o. until disease progression

DRUG

Pemetrexed

pemetrexed 500 mg/m2 intravenously every 3 weeks until disease progression

DRUG

Carboplatin

carboplatin area under curve 5 intravenously every 3 weeks for four cycles

Trial Locations (2)

510060

Department of Medical Oncology,Cancer Center of Sun Yat-Sen University, Guangzhou

Unknown

Central Hospital of Guangdong Nongken, Zhanjiang Cancer Hospital, Zhanjiang

All Listed Sponsors
collaborator

Cancer Hospital of Guangxi Medical University

OTHER

collaborator

First People's Hospital of Foshan

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

lead

Li Zhang, MD

OTHER